The significant Q1 beat and positive pipeline updates (WVE-007 Phase 2a, WVE-006 data) are likely to drive the stock higher. Monitor the ATS conference in May for WVE-006 data and any regulatory feedback on accelerated approval.
WVE drugs
WVE drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 28 $7.52entry
- T+1 · 7mo ago −6.25%α −6.24% · $7.05
- T+5 · 7mo ago −0.66%α −2.36% · $7.47
- T+20 · 6mo ago −15.16%α −20.63% · $6.38
- T+60 · 4mo ago −23.14%α −27.13% · $5.78
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Wave Life Sciences reported Q1 2026 revenue of $38.2M (vs consensus $7.9M) and EPS of -$0.13 (vs consensus -$0.31), representing a massive beat. Net loss improved to $26.1M from $46.9M a year ago, and the company maintained a strong cash position of $544.6M. Pipeline catalysts include FDA acceptance of WVE-007 Phase 2a and upcoming AATD data.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $38.2M vs consensus $7.9M (beat by 384%)
- Q1 2026 EPS -$0.13 vs consensus -$0.31 (beat by 58%)
- Net loss improved to $26.1M from $46.9M YoY
- Cash and equivalents $544.6M, runway into Q3 2028
- FDA accepted Phase 2a multidose portion for WVE-007 (obesity), initiation on track for Q2 2026
- WVE-006 AATD data at ATS in May 2026; regulatory feedback on accelerated approval expected mid-2026
Financial Impact
Revenue beat of $30.3M vs consensus; EPS beat of $0.18; net loss improved by $20.8M YoY
Risk Factors
- Clinical trial delays or failures for WVE-007 and WVE-006
- Dilution from increased share count (200M vs 163M YoY)
- Still in net loss, though improving
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3282474 |
Track record
16 reports on WVE
3 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +17.42% at T+5 after the Mar 26, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $3.13 to $2.87 Now $2.87 −8.31% ▼ −8.31% −6.40% vs SPY
- Oct 27, 202620d ago SC 13G Neutral 4/10 Entry $3.64 to $3.63 Now $2.87 −21.15% ▼ −0.27% +0.11% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $3.45 to $3.64 Now $2.87 −16.81% ▲ +5.51% +5.16% vs SPY
- Oct 27, 202620d ago 8-K Bullish 6/10 No price data
- Oct 27, 202620d ago Press Release Neutral 5/10 Entry $3.45 to $3.64 Now $2.87 −16.81% ▲ +5.51% +5.16% vs SPY
- Oct 14, 20264w ago DEF 14A Neutral 4/10 Entry $3.19 to $3.13 Now $2.87 −10.03% ▼ −1.88% −0.77% vs SPY
- Sep 30, 20266w ago Press Release Bullish 5/10 Entry $3.70 to $3.88 Now $2.87 −22.43% ▲ +4.86% +4.69% vs SPY
- Aug 13, 202613w ago Insider Cluster Neutral 3/10 Entry $5.41 to $5.09 Now $2.87 −46.95% ▼ −5.92% −5.44% vs SPY
- May 18, 202626w ago Press Release Bullish 7/10 Entry $6.14 to $6.19 Now $2.87 −53.26% ▲ +0.81% −0.23% vs SPY
- Apr 28, 202628w ago 8-K Bullish 7/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers